GRAMD2B, whose full name might not be as commonly known, is a gene. However, based on the reference, its function seems to be associated with the regulation of serum leucocyte concentration [1]. While the reference doesn't elaborate on the exact associated pathways, it indicates a potential role in processes related to the immune system considering the leucocyte connection. Genetic models, such as KO/CKO mouse models, could potentially be valuable in further exploring its functions.

In a genome-wide association study on coronary artery disease in type 1 diabetes, among eight suggestive loci, the rs2112481 on the GRAMD2B promoter was associated with serum leucocyte concentration [1]. This finding implies that GRAMD2B might play a role in the context of type 1 diabetes-related coronary artery disease, potentially through its influence on leucocyte levels.

In conclusion, GRAMD2B appears to have a function related to the regulation of serum leucocyte concentration, which may be relevant in the context of type 1 diabetes-associated coronary artery disease. The discovery in the study provides a starting point for further in-vivo studies, especially using KO/CKO mouse models, to better understand its role in these disease-related biological processes.

References:

1. Antikainen, Anni A V, Sandholm, Niina, Trégouët, David-Alexandre, Rossing, Peter, Groop, Per-Henrik. . Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. In Cardiovascular research, 117, 600-612. doi:10.1093/cvr/cvaa045. https://pubmed.ncbi.nlm.nih.gov/32077919/